Stockscreener 앱 받기
30.88
0.19%
-0.06
시간 외 거래:
30.58
-0.30
-0.97%
전일 마감가:
$30.94
열려 있는:
$31.26
하루 거래량:
1.60M
Relative Volume:
0.71
시가총액:
$4.54B
수익:
$264.79M
순이익/손실:
$-14.36M
주가수익비율:
-280.73
EPS:
-0.11
순현금흐름:
$-28.11M
1주 성능:
+0.55%
1개월 성능:
+3.42%
6개월 성능:
+23.18%
1년 성능:
+137.17%
1일 변동 폭
$30.37
$31.50
1주일 범위
$29.73
$31.57
52주 변동 폭
$12.90
$36.84
TG테라퓨틱스사 Stock (TGTX) Company Profile
명칭
Tg Therapeutics Inc
전화
(212) 554-4484
주소
2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY
TGTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TGTX
Tg Therapeutics Inc
|
30.88 | 4.54B | 264.79M | -14.36M | -28.11M | -0.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
TG테라퓨틱스사 Stock (TGTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-29 | 개시 | TD Cowen | Buy |
| 2023-08-02 | 업그레이드 | Goldman | Sell → Neutral |
| 2023-06-26 | 재개 | Jefferies | Buy |
| 2022-05-20 | 개시 | BofA Securities | Underperform |
| 2022-02-23 | 재확인 | B. Riley Securities | Buy |
| 2021-11-15 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-04-20 | 개시 | Goldman | Neutral |
| 2021-04-19 | 재확인 | H.C. Wainwright | Buy |
| 2020-09-01 | 개시 | JP Morgan | Overweight |
| 2020-08-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-05 | 개시 | Evercore ISI | Outperform |
| 2020-01-17 | 재확인 | H.C. Wainwright | Buy |
| 2019-11-27 | 재개 | B. Riley FBR | Buy |
| 2019-02-06 | 재개 | Jefferies | Buy |
| 2018-09-25 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2018-03-09 | 재확인 | B. Riley FBR, Inc. | Buy |
| 2017-12-01 | 재개 | B. Riley FBR, Inc. | Buy |
| 2017-11-14 | 재개 | H.C. Wainwright | Buy |
| 2017-04-25 | 개시 | Jefferies | Buy |
| 2017-03-06 | 재확인 | FBR & Co. | Outperform |
| 2016-10-06 | 재개 | Brean Capital | Buy |
| 2016-05-27 | 개시 | SunTrust | Buy |
| 2015-12-01 | 개시 | FBR Capital | Outperform |
| 2015-09-09 | 개시 | Raymond James | Strong Buy |
| 2015-08-12 | 재개 | H.C. Wainwright | Buy |
| 2015-06-19 | 재확인 | Brean Capital | Buy |
| 2014-12-11 | 재확인 | ROTH Capital | Buy |
| 2014-12-10 | 재확인 | ROTH Capital | Buy |
모두보기
TG테라퓨틱스사 주식(TGTX)의 최신 뉴스
TG Therapeutics Announces Schedule of Data Presentations - GlobeNewswire
Groundbreaking BRIUMVI MS Treatment Data: 4 Critical Studies Reveal Real-World Impact at ACTRIMS - StockTitan
TG Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
TG Therapeutics Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before September 16, 2022 to Discuss Your RightsTGTX - Newsfile
TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Sold by Entropy Technologies LP - MarketBeat
Bleakley Financial Group LLC Purchases Shares of 8,140 TG Therapeutics, Inc. (NASDAQ:TGTX) - MarketBeat
TG Therapeutics to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform to support the development and commercialization of azer-cel, its allogeneic CD19 CAR T cell therapy program, for the treatment of autoimmune diseases - MSN
TG Therapeutics Licenses Maxcyte Tech to Develop Cell Therapies for Autoimmune Disease - Genetic Engineering & Biotechnology News
46,655 Shares in TG Therapeutics, Inc. (NASDAQ:TGTX) Bought by Strategic Financial Concepts LLC - MarketBeat
How Small, But 'Mighty' TG Therapeutics Scored A 470% Gain Over 13 Months - Yahoo
MaxCyte Signs Licensing Deal With TG Therapeutics For Next-Gen Autoimmune Cell Therapies - Nasdaq
MaxCyte signs SPL deal with TG Therapeutics - ShareCast
MaxCyte Signs Platform License Deal With TG Therapeutics -February 12, 2025 at 05:07 am EST - Marketscreener.com
MaxCyte, TG Therapeutics sign strategic platform license to advance autoimmune cell therapeutics programs - MSN
MaxCyte Licenses Cell-Engineering Technology to TG Therapeutics -February 12, 2025 at 04:37 am EST - Marketscreener.com
Major Autoimmune Breakthrough: MaxCyte Technology Powers Next-Gen Multiple Sclerosis Treatment - StockTitan
MaxCyte Partners with TG Therapeutics for Autoimmune Cell Therapy - TipRanks
MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs - The Manila Times
Maxcyte Says Enters Strategic Platform License With TG Therapeutics -February 12, 2025 at 02:18 am EST - Marketscreener.com
MaxCyte Enters Strategic License Agreement with TG Therapeutics for Cell-Based Therapy Development - Nasdaq
MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell ... - The Bakersfield Californian
SG Americas Securities LLC Has $233,000 Stock Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX) - MarketBeat
Stratos Wealth Advisors LLC Acquires New Stake in TG Therapeutics, Inc. (NASDAQ:TGTX) - MarketBeat
Institutional investors are TG Therapeutics, Inc.'s (NASDAQ:TGTX) biggest bettors and were rewarded after last week's US$199m market cap gain - Simply Wall St
TG Therapeutics, Inc. (NASDAQ:TGTX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
TGTX March 28th Options Begin Trading - Nasdaq
Symphony Financial Ltd. Co. Acquires New Shares in TG Therapeutics, Inc. (NASDAQ:TGTX) - MarketBeat
Precision Wealth Strategies LLC Makes New $530,000 Investment in TG Therapeutics, Inc. (NASDAQ:TGTX) - MarketBeat
TG Therapeutics (NASDAQ:TGTX) Rating Lowered to "Sell" at StockNews.com - MarketBeat
Nisa Investment Advisors LLC Buys 2,803 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) - Defense World
Trading (TGTX) With Integrated Risk Controls - Stock Traders Daily
All You Need to Know About TG Therapeutics (TGTX) Rating Upgrade to Buy - MSN
TG Therapeutics (NASDAQ:TGTX) Stock Price Up 6.8%Here's What Happened - MarketBeat
Why TGTX Stock Is Rallying Today - MSN
TG Therapeutics: Entering 2025 With Increased Investor Expectations (NASDAQ:TGTX) - Seeking Alpha
Cantor Fitzgerald Weighs in on TG Therapeutics FY2025 Earnings - Defense World
Assenagon Asset Management S.A. Decreases Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX) - MarketBeat
TG Therapeutics: 2025 Revenues Will Smash Expectations (NASDAQ:TGTX) - Seeking Alpha
12 Hot Stocks to Buy According to Analysts - Insider Monkey
Here’s Why Analysts Are Bullish on TG Therapeutics, Inc. (TGTX) - Insider Monkey
TG Therapeutics (TGTX) Moves 7.5% Higher: Will This Strength Last? - MSN
(TGTX) Trading Signals - Stock Traders Daily
Brookstone Capital Management Acquires 624 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) - Defense World
FY2024 EPS Forecast for TG Therapeutics Increased by Analyst - Defense World
Is TG Therapeutics Inc. (TGTX) Among Tuesday’s Top Gainers? - MSN
TG Therapeutics FY2024 EPS Forecast Raised by HC Wainwright - MarketBeat
TG Therapeutics Provides Preliminary Fourth Quarter and Full-Year Financial Results in SEC Filing - Defense World
TG Therapeutics: Cash Positive But Playing Defense (Rating Downgrade) (NASDAQ:TGTX) - Seeking Alpha
TG Therapeutics FY2025 EPS Forecast Raised by HC Wainwright - MarketBeat
TG Therapeutics' (TGTX) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
TGTX Announces 2024 Preliminary Results, 2025 Goals, Shares Rise - MSN
TG테라퓨틱스사 (TGTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.27%
3.05%
자본화:
|
볼륨(24시간):